Combined hormonal contraceptive vaginal ring

Provenance

Written by SPS and the College of Sexual and Reproductive Healthcare (CoSRH), with the support of specialist stakeholders working within clinical practice, for use within reproductive services.

Under Review – June 2026

The CoSRH Statement: Meningioma and Progestogens published on the 4th June 2026 will require all the contraception PGD templates to be reviewed to ensure this new advice is reflected.

The Short Life Working Group will complete this review with the aim that any templates requiring an update will be republished by the end of July 2026.

If any organisation wishes to reflect the guidance within the local templates before this review has taken place they may do so in line with local policies.

PGD template attachment

The template PGD is attached below to download and use in conjunction with our implementation advice (SPS page).

• CHC ring National PGD template accessible V3.1 01.26Opens in a new window · Word · 82 KB

Patient Group Directions, Templates, Reproductive health

• Progestogen-Only Intra-Uterine Device (LNG-IUD) for contraception
• Etonogestrel (e.g. Nexplanon®) implant for contraception
• Combined hormonal contraceptive transdermal patch
• Medroxyprogesterone acetate (SC-DMPA) injection for contraception
• Ulipristal acetate 30mg tablets for emergency contraception
• Progestogen only pill (POP) for contraception
• Levonorgestrel 1500 microgram tablets for emergency contraception
• Combined oral hormonal contraceptive (COC) in reproductive health
• Medroxyprogesterone acetate (DMPA) IM injection for contraception
• Lidocaine injection for subdermal etonogestrel in contraception
• Lidocaine plus prilocaine cream for IUD insertion or removal
• Lidocaine 10mg/ml spray for IUD insertion or removal
• Copper Intrauterine Device (Cu-IUD)

Update history